Get the Stockscreener App
1.62
3.57%
-0.06
After Hours:
1.62
iBio Inc stock is traded at $1.62, with a volume of 465.62K.
It is down -3.57% in the last 24 hours and down -10.99% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$1.68
Open:
$1.71
24h Volume:
465.62K
Relative Volume:
0.51
Market Cap:
$80.48M
Revenue:
$300.00K
Net Income/Loss:
$-27.61M
P/E Ratio:
-2.8042
EPS:
-0.5777
Net Cash Flow:
$-22.17M
1W Performance:
-6.36%
1M Performance:
-10.99%
6M Performance:
-21.36%
1Y Performance:
+118.62%
1-Day Range:
$1.62
$1.74
1-Week Range:
$1.62
$2.11
52-Week Range:
$0.5562
$3.82
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.62 | 86.94M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
IBIO Maintained by Chardan Capital -- Price Target Stays at $5.0 - GuruFocus
$IBIO stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
iBio’s IBIO-610 Antibody Achieves 98% Activin E Inhibition and Boosts Fat Loss in Obese Primates, Outperforming Semaglutide Alone 1 - Minichart
iBio Highlights Promising New Preclinical Obesity Antibody Data - TipRanks
Innovative Findings on IBIO-610 from iBio - GuruFocus
iBio (NASDAQ: IBIO) obesity antibody cuts Activin E and spares lean mass - Stock Titan
iBio Inc. announced research results showing that a single administration of the candidate drug IBIO-610 in an obese non-human primate model achieved nearly complete inhibition of active activin E for up to eight weeks. - Bitget
iBio drug held Activin E down for 8 weeks in obese primates - Stock Titan
IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Value Benchmark Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell 3000E Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Index - marketscreener.com
Enterprise value to revenue forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Price to book forward of iBio, Inc. – NASDAQ:IBIO - TradingView
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery - Fierce Biotech
iBio, Inc. Actuals & Estimates (NASDAQ:IBIO) - TradingView
0JV0 Forecast — Price Target — Prediction for 2027 - TradingView
IBIO Forecast — Price Target — Prediction for 2027 - TradingView
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
iBio Inc (IBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
iBio Inc (IBIO) Institutional Confidence - TradingKey
Top iBio (IBIO) Competitors 2026 - MarketBeat
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
IBIO News | IBIO INC (NASDAQ:IBIO) - ChartMill
IBIO - Finviz
iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
iBio Inc (IBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
iBio Inc (IBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
iBio Inc (IBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Raymond James Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
iBio Inc. (IBIO) Edges Higher as Biotech Sector Shows Cautious OptimismBollinger Expansion - newsline.com
Could iBio (IBIO) Be an Underrated Obesity Stock? - Insider Monkey
5 Under-the-Radar AI Stocks to Buy in 2026 - Insider Monkey
iBio Inc. (IBIO) Nears Key Support Amid Slight Decline: Technical AnalysisQuote Data - newsline.com
IBIO Initiates Coverage On Raymond James -- Rating Set to Outper - GuruFocus
IBIO Initiates Coverage On Raymond James -- Rating Set to Outperform - GuruFocus
Raymond James initiates iBio stock coverage with outperform rating By Investing.com - Investing.com South Africa
Raymond James initiates iBio stock coverage with outperform rating - Investing.com
iBio Inc. (IBIO) Q1 2026 Earnings: EPS Misses Estimates as Biotech Firm Reports No RevenueEarnings Growth Forecast - newsline.com
B. Riley Initiates IBio at Buy With $6 Price Target - Moomoo
IBIO: Advancing antibody-based therapies for obesity, muscle preservation, and weight maintenance - TradingView
IBIO: Advancing antibody-based therapies for obesity and weight maintenance with key clinical milestones ahead - TradingView
iBio to Participate in Upcoming Healthcare Investor Conferences - The Manila Times
AI drug developer iBio joins two health investor events in June and July 2026 - Stock Titan
iBio doses first patient in obesity drug trial - Investing.com UK
iBio (IBIO) Begins Phase 1 Clinical Trial for IBIO-600 - GuruFocus
iBio doses first patient in obesity drug trial By Investing.com - Investing.com Australia
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity - The Manila Times
iBio tests long-acting obesity antibody designed to preserve muscle - Stock Titan
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
iBio Inc Stock (IBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Duran Felipe | Chief Financial Officer |
Mar 19 '26 |
Buy |
2.02 |
24,835 |
50,132 |
35,974 |
| Brenner Martin | See Remarks |
Mar 19 '26 |
Buy |
2.02 |
12,336 |
24,919 |
30,652 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):